<a class="ci-mono font-sans text-ink no-underline hover:text-accent" href="/gene/NTRK3">NTRK3 Fusion

Predictive

Supports Sensitivity Response

accepted

EID7994

Two AML cell lines, IMS-M2 and M0-91, with the ETV6-NTRK3 fusion were treated with entrectinib. Sequencing of these cell lines found no other driver mutations in 265 other cancer genes suggesting the… (full text at CIViC)

PMID 29237803 · Smith et al., 2018 · Open in CIViC

Anaplastic Astrocytoma1

ETV6::NTRK3 Fusion

Anaplastic Sarcoma of the Kidney1

Predictive

Supports Sensitivity Response

accepted

EID11853

In a phase 1/2 trial of entrectinib in pediatric patients, tumors with fusions in NTRK, ROS1, or ALK had an overall response (ORR) of 57.7% (95% CI; 36.9-76.7). This included one patient (2 months ol… (full text at CIViC)

PMID 35395680 ·

Anaplastic Sarcoma of the Kidney1
ETV6::NTRK3 Fusion	(diagnostic)	Diagnostic	C	Does Not Support Negative	1	submitted	EID10421 In 4 cases of Anaplastic sarcoma of the kidney ETV6::NTRK3 fusion was negative. PMID 17895746 · Vujanić et al., 2007 · Open in CIViC	civic

ETV6::NTRK3 Fusion

(diagnostic)

Diagnostic

Does Not Support Negative

submitted

EID10421

In 4 cases of Anaplastic sarcoma of the kidney ETV6::NTRK3 fusion was negative.

PMID 17895746 · Vujanić et al., 2007 · Open in CIViC

B Lymphoblastic Leukemia/Lymphoma5

B Lymphoblastic Leukemia/Lymphoma5
ETV6::NTRK3 Fusion	(oncogenic)	Oncogenic	D	Supports Oncogenicity	4	accepted	EID8931 The tyrosine kinase domain of NTRK3 was inserted into exon 6 of Etv6 to create conditional knock-in Etv6-NTRK3 mice . Expression was induced in pre-b cells during lymphoid development by CD19-Cre. Fus… (full text at CIViC) PMID 29880614 · Roberts et al., 2018 · Open in CIViC	civic
ETV6::NTRK3 Fusion	Larotrectinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID7993 Case report of a 61-year-old man with B-ALL. An initial analysis detected the ETV6-NTRK3 fusion and a NRASGly12Asp mutation. Initial therapies included chemotherapy and CAR-T infusion. Relapse 6 weeks… (full text at CIViC) PMID 31905241 · Nardi et al., 2020 · Open in CIViC	civic
ETV6::NTRK3 Fusion	Larotrectinib	Predictive	D	Supports Sensitivity Response	4	accepted	EID6930 Both in vivo and in vitro models demonstrated Larotrectinib was an effective treatment against cells harboring ETV6-NTRK3. In YFP-luciferase PDX mice from a 16-year-old with Ph-like B-ALL, flow cytome… (full text at CIViC) PMID 29880614 · Roberts et al., 2018 · Open in CIViC	civic
ETV6::NTRK3 Fusion	Larotrectinib	Predictive	D	Supports Sensitivity Response	3	accepted	EID8930 Conventional cytogenetics, FISH, and an Abbott break-apart probe of a peripheral blood sample collected at diagnosis of a 6-year-old boy with B-cell ALL and CNS infiltration (National Cancer Institute… (full text at CIViC) PMID 31725893 · Schewe et al., 2019 · Open in CIViC	civic
ETV6::NTRK3 Fusion	Etoposide + Larotrectinib + MethotrexateCombination	Predictive	C	Supports Sensitivity Response	4	accepted	EID8917 All lines of conventional therapy (including allogeneic HSCT, blinatumomab, and CAR T cells) were inefficient for a 6-year-old boy with B-cell ALL and CNS infiltration (National Cancer Institute high … (full text at CIViC) PMID 31725893 · Schewe et al., 2019 · Open in CIViC	civic

ETV6::NTRK3 Fusion

(oncogenic)

Oncogenic

Supports Oncogenicity

accepted

EID8931

The tyrosine kinase domain of NTRK3 was inserted into exon 6 of Etv6 to create conditional knock-in Etv6-NTRK3 mice . Expression was induced in pre-b cells during lymphoid development by CD19-Cre. Fus… (full text at CIViC)

PMID 29880614 · Roberts et al., 2018 · Open in CIViC

ETV6::NTRK3 Fusion

Predictive

Supports Sensitivity Response

accepted

EID7993

Case report of a 61-year-old man with B-ALL. An initial analysis detected the ETV6-NTRK3 fusion and a NRASGly12Asp mutation. Initial therapies included chemotherapy and CAR-T infusion. Relapse 6 weeks… (full text at CIViC)

PMID 31905241 · Nardi et al., 2020 · Open in CIViC

ETV6::NTRK3 Fusion

Predictive

Supports Sensitivity Response

accepted

EID6930

Both in vivo and in vitro models demonstrated Larotrectinib was an effective treatment against cells harboring ETV6-NTRK3. In YFP-luciferase PDX mice from a 16-year-old with Ph-like B-ALL, flow cytome… (full text at CIViC)

PMID 29880614 · Roberts et al., 2018 · Open in CIViC

ETV6::NTRK3 Fusion

Predictive

Supports Sensitivity Response

accepted

EID8930

Conventional cytogenetics, FISH, and an Abbott break-apart probe of a peripheral blood sample collected at diagnosis of a 6-year-old boy with B-cell ALL and CNS infiltration (National Cancer Institute… (full text at CIViC)

PMID 31725893 · Schewe et al., 2019 · Open in CIViC

ETV6::NTRK3 Fusion

Etoposide + Larotrectinib + MethotrexateCombination

Predictive

Supports Sensitivity Response

accepted

EID8917

All lines of conventional therapy (including allogeneic HSCT, blinatumomab, and CAR T cells) were inefficient for a 6-year-old boy with B-cell ALL and CNS infiltration (National Cancer Institute high … (full text at CIViC)

PMID 31725893 · Schewe et al., 2019 · Open in CIViC

B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like1

B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like1
ETV6::NTRK3 Fusion	(diagnostic)	Diagnostic	C	Supports Positive	1	submitted	EID12295 Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukemia (ALL) is a high-risk subtype characterised by genomic alterations that activate cytokine receptor and kinase signaling. The author e… (full text at CIViC) PMID 28408464 · Reshmi et al., 2017 · Open in CIViC	civic

ETV6::NTRK3 Fusion

(diagnostic)

Diagnostic

Supports Positive

submitted

EID12295

Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukemia (ALL) is a high-risk subtype characterised by genomic alterations that activate cytokine receptor and kinase signaling. The author e… (full text at CIViC)

PMID 28408464 · Reshmi et al., 2017 · Open in CIViC

Breast Secretory Carcinoma6

Breast Secretory Carcinoma6
ETV6::NTRK3 Fusion	(diagnostic)	Diagnostic	B	Supports Positive	3	submitted	EID10503 A 6-year-old female had invasive breast adenocarcinoma with the histopathologic features of a secretory breast carcinoma (SBC). FISH and RT-PCR on frozen tumor tissue found ETV6::NTRK3 fusion. 11 of … (full text at CIViC) PMID 12450792 · Tognon et al., 2002 · Open in CIViC	civic
ETV6::NTRK3 Fusion	(diagnostic)	Diagnostic	B	Supports Positive	3	accepted	EID11343 In developing a FISH assay to detect ETV6::NTRK3 fusions, the authors found 3 of 4 secretary breast carcinomas were positive for the fusion. In a subsequent analysis of an invasive breast carcinoma t… (full text at CIViC) PMID 15101049 · Makretsov et al., 2004 · Open in CIViC	civic
ETV6::NTRK3 Fusion	(diagnostic)	Diagnostic	B	Supports Positive	3	accepted	EID11344 12 of 13 (92%) secretory breast carcinomas were found to have ETV6::NTRK3 fusions by RT-PCR and/or FISH whereas other infiltrating ductal carcinomas were negative for the fusion. PMID 12450792 · Tognon et al., 2002 · Open in CIViC	civic
ETV6::NTRK3 Fusion	(diagnostic)	Diagnostic	B	Supports Positive	3	accepted	EID11345 9 of 9 breast secretory carcinomas were found to have ETV6:NTRK3 fusions, a basal-like phenotype, and no additional pathogenic aberrations in genes commonly mutated in breast cancer. PMID 28548128 · Krings et al., 2017 · Open in CIViC	civic
ETV6::NTRK3 Fusion	(oncogenic)	Oncogenic	D	Supports Oncogenicity	3	accepted	EID10504 A 6-year-old female was diagnosed with secretory breast carcinoma (SBC), a rare invasive breast adenocarcinoma. Analysis of the tumor revealed a genetic driver: an ETV6::NTRK3 gene fusion. This fusion… (full text at CIViC) PMID 12450792 · Tognon et al., 2002 · Open in CIViC	civic
ETV6::NTRK3 Fusion	Larotrectinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID6475 Shukla et al report on a remarkable case study of a 14 year old pediatric patient with refractory secretory breast carcinoma first presenting as a fibroadenoma at 8 yo. Over the next years, she experi… (full text at CIViC) PMID 29623306 · Shukla et al., 2017 · Open in CIViC	civic

ETV6::NTRK3 Fusion

(diagnostic)

Diagnostic

Supports Positive

submitted

EID10503

A 6-year-old female had invasive breast adenocarcinoma with the histopathologic features of a secretory breast carcinoma (SBC). FISH and RT-PCR on frozen tumor tissue found ETV6::NTRK3 fusion. 11 of … (full text at CIViC)

PMID 12450792 · Tognon et al., 2002 · Open in CIViC

ETV6::NTRK3 Fusion

(diagnostic)

Diagnostic

Supports Positive

accepted

EID11343

In developing a FISH assay to detect ETV6::NTRK3 fusions, the authors found 3 of 4 secretary breast carcinomas were positive for the fusion. In a subsequent analysis of an invasive breast carcinoma t… (full text at CIViC)

PMID 15101049 · Makretsov et al., 2004 · Open in CIViC

ETV6::NTRK3 Fusion

(diagnostic)

Diagnostic

Supports Positive

accepted

EID11344

12 of 13 (92%) secretory breast carcinomas were found to have ETV6::NTRK3 fusions by RT-PCR and/or FISH whereas other infiltrating ductal carcinomas were negative for the fusion.

PMID 12450792 · Tognon et al., 2002 · Open in CIViC

ETV6::NTRK3 Fusion

(diagnostic)

Diagnostic

Supports Positive

accepted

EID11345

9 of 9 breast secretory carcinomas were found to have ETV6:NTRK3 fusions, a basal-like phenotype, and no additional pathogenic aberrations in genes commonly mutated in breast cancer.

PMID 28548128 · Krings et al., 2017 · Open in CIViC

ETV6::NTRK3 Fusion

(oncogenic)

Oncogenic

Supports Oncogenicity

accepted

EID10504

A 6-year-old female was diagnosed with secretory breast carcinoma (SBC), a rare invasive breast adenocarcinoma. Analysis of the tumor revealed a genetic driver: an ETV6::NTRK3 gene fusion. This fusion… (full text at CIViC)

PMID 12450792 · Tognon et al., 2002 · Open in CIViC

ETV6::NTRK3 Fusion

Predictive

Supports Sensitivity Response

accepted

EID6475

Shukla et al report on a remarkable case study of a 14 year old pediatric patient with refractory secretory breast carcinoma first presenting as a fibroadenoma at 8 yo. Over the next years, she experi… (full text at CIViC)

PMID 29623306 · Shukla et al., 2017 · Open in CIViC

Congenital Mesoblastic Nephroma5

Congenital Mesoblastic Nephroma5
ETV6::NTRK3 Fusion	(diagnostic)	Diagnostic	B	Supports Positive	3	accepted	EID10841 A frequent genetic alteration in congenital mesoblastic nephroma is the translocation t(12;15) resulting in a fusion of the ETV6 gene on 12p13 and the NTRK3 gene on 15p15 that occurs almost exclusivel… (full text at CIViC) PMID 29286563 · Vokuhl et al., 2018 · Open in CIViC	civic
ETV6::NTRK3 Fusion	(prognostic)	Prognostic	B	Supports Better Outcome	3	submitted	EID10842 In a group of 111 mesoblastic nephroma (MN) samples, 79 were were evaluable by FISH, which consisted of 38 classical MN, 29 cellular MN, and 12 mixed MN samples. 5 year relapse free survival (RFS) was… (full text at CIViC) PMID 29286563 · Vokuhl et al., 2018 · Open in CIViC	civic
ETV6::NTRK3 Fusion	(diagnostic)	Diagnostic	B	Supports Positive	3	accepted	EID11279 In an analysis of 19 cases of mesoblastic nephroma, the ETV6::NTRK3 fusion was detected in 0 of 5 of the classic mesoblastic nephroma, 8 of 8 (100%) of the cellular mesoblastic nephroma and 5 of 6 (83… (full text at CIViC) PMID 27020209 · El Demellawy et al., 2016 · Open in CIViC	civic
ETV6::NTRK3 Fusion	(diagnostic)	Diagnostic	B	Supports Positive	2	accepted	EID11280 In an analysis of 22 cases of mesoblastic nephroma, 4 of 5 (80%) cellular mesoblastic nephromas harbored ETV6::NTRK3, 1 of 5 cellular mesoblastic nephromas harbored a KLHL7::BRAF fusion, 12 of 12 (100… (full text at CIViC) PMID 32590884 · Zhao et al., 2020 · Open in CIViC	civic
ETV6::NTRK3 Fusion	Larotrectinib	Predictive	C	Supports Sensitivity Response	4	accepted	EID10840 A 23 month old (at the time of report) male was diagnosed prenatally with Stage II cellular mesoblastic nephroma (MN) on the right kidney, which was surgically removed on the sixth day of life. ETV6::… (full text at CIViC) PMID 29893456 · Halalsheh et al., 2018 · Open in CIViC	civic

ETV6::NTRK3 Fusion

(diagnostic)

Diagnostic

Supports Positive

accepted

EID10841

A frequent genetic alteration in congenital mesoblastic nephroma is the translocation t(12;15) resulting in a fusion of the ETV6 gene on 12p13 and the NTRK3 gene on 15p15 that occurs almost exclusivel… (full text at CIViC)

PMID 29286563 · Vokuhl et al., 2018 · Open in CIViC

ETV6::NTRK3 Fusion

(prognostic)

Prognostic

Supports Better Outcome

submitted

EID10842

In a group of 111 mesoblastic nephroma (MN) samples, 79 were were evaluable by FISH, which consisted of 38 classical MN, 29 cellular MN, and 12 mixed MN samples. 5 year relapse free survival (RFS) was… (full text at CIViC)

PMID 29286563 · Vokuhl et al., 2018 · Open in CIViC

ETV6::NTRK3 Fusion

(diagnostic)

Diagnostic

Supports Positive

accepted

EID11279

In an analysis of 19 cases of mesoblastic nephroma, the ETV6::NTRK3 fusion was detected in 0 of 5 of the classic mesoblastic nephroma, 8 of 8 (100%) of the cellular mesoblastic nephroma and 5 of 6 (83… (full text at CIViC)

PMID 27020209 · El Demellawy et al., 2016 · Open in CIViC

ETV6::NTRK3 Fusion

(diagnostic)

Diagnostic

Supports Positive

accepted

EID11280

In an analysis of 22 cases of mesoblastic nephroma, 4 of 5 (80%) cellular mesoblastic nephromas harbored ETV6::NTRK3, 1 of 5 cellular mesoblastic nephromas harbored a KLHL7::BRAF fusion, 12 of 12 (100… (full text at CIViC)

PMID 32590884 · Zhao et al., 2020 · Open in CIViC

ETV6::NTRK3 Fusion

Predictive

Supports Sensitivity Response

accepted

EID10840

A 23 month old (at the time of report) male was diagnosed prenatally with Stage II cellular mesoblastic nephroma (MN) on the right kidney, which was surgically removed on the sixth day of life. ETV6::… (full text at CIViC)

PMID 29893456 · Halalsheh et al., 2018 · Open in CIViC

Gastrointestinal Stromal Tumor1

Gastrointestinal Stromal Tumor1
ETV6::NTRK3 Fusion	Entrectinib	Predictive	C	Supports Sensitivity Response	2	submitted	EID12527 Plasma ctDNA analysis detected an ETV6:NTRK3 fusion (described by the authors as "ETV6 exon4:NTRK3 exon14" at a VAF of 35.3%) in a female patient with recurrent GIST. Entrectinib therapy (600 mg daily… (full text at CIViC) PMID 40900786 · Dong et al., 2025 · Open in CIViC	civic

ETV6::NTRK3 Fusion

Predictive

Supports Sensitivity Response

submitted

EID12527

Plasma ctDNA analysis detected an ETV6:NTRK3 fusion (described by the authors as "ETV6 exon4:NTRK3 exon14" at a VAF of 35.3%) in a female patient with recurrent GIST. Entrectinib therapy (600 mg daily… (full text at CIViC)

PMID 40900786 · Dong et al., 2025 · Open in CIViC

Glioblastoma1
ETV6::NTRK3 Fusion	Entrectinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID11848 In a phase 1/2 trial of entrectinib in pediatric patients, tumors with fusions in NTRK, ROS, or ALK had an overall response (ORR) of 57.7% (95% CI; 36.9-76.7). This included one patient (3 yo) with a… (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC	civic

Glioblastoma1

ETV6::NTRK3 Fusion

Predictive

Supports Sensitivity Response

accepted

EID11848

In a phase 1/2 trial of entrectinib in pediatric patients, tumors with fusions in NTRK, ROS, or ALK had an overall response (ORR) of 57.7% (95% CI; 36.9-76.7). This included one patient (3 yo) with a… (full text at CIViC)

PMID 35395680 · Desai et al., 2022 · Open in CIViC

Gliosarcoma1
ETV6::NTRK3 Fusion	(oncogenic)	Oncogenic	C	Supports Oncogenicity	2	submitted	EID12603 In the STARTRK-NG Phase 1/2 trial of entrectinib in pediatric patients, one patient (4 yo) with Biphasic and spindled epithelioid glial neoplasm had ETV6::NTRK3 fusion. The patient received che… (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC	civic

Gliosarcoma1

ETV6::NTRK3 Fusion

(oncogenic)

Oncogenic

Supports Oncogenicity

submitted

EID12603

In the STARTRK-NG Phase 1/2 trial of entrectinib in pediatric patients, one patient (4 yo) with Biphasic and spindled epithelioid glial neoplasm had ETV6::NTRK3 fusion. The patient received che… (full text at CIViC)

PMID 35395680 · Desai et al., 2022 · Open in CIViC

Hematopoietic and Lymphoid Cell Neoplasm1

Hematopoietic and Lymphoid Cell Neoplasm1
ETV6::NTRK3 Fusion	Larotrectinib	Predictive	C	Supports Sensitivity Response	3	submitted	EID6395 Rearrangements involving the neurotrophic receptor kinase genes (NTRK1, NTRK2, and NTRK3; hereafter referred to as TRK) produce oncogenic fusions in a wide variety of cancers in adults and children. I… (full text at CIViC) PMID 29920189 · Taylor et al., 2018 · Open in CIViC	civic

ETV6::NTRK3 Fusion

Predictive

Supports Sensitivity Response

submitted

EID6395

Rearrangements involving the neurotrophic receptor kinase genes (NTRK1, NTRK2, and NTRK3; hereafter referred to as TRK) produce oncogenic fusions in a wide variety of cancers in adults and children. I… (full text at CIViC)

PMID 29920189 · Taylor et al., 2018 · Open in CIViC

High-Grade Glioma, NOS1
ETV6::NTRK3 Fusion	Larotrectinib	Predictive	C	Supports Sensitivity Response	3	submitted	EID10931 A 3 year old patient was initially diagnosed with a high grade glioma at 5 months of age. She was treated with 13 cycles of chemotherapy. 4 months after completing initial treatment, she showed progre… (full text at CIViC) PMID 30220707 · Ziegler et al., 2018 · Open in CIViC	civic

High-Grade Glioma, NOS1

ETV6::NTRK3 Fusion

Predictive

Supports Sensitivity Response

submitted

EID10931

A 3 year old patient was initially diagnosed with a high grade glioma at 5 months of age. She was treated with 13 cycles of chemotherapy. 4 months after completing initial treatment, she showed progre… (full text at CIViC)

PMID 30220707 · Ziegler et al., 2018 · Open in CIViC

Infantile Fibrosarcoma9
ETV6::NTRK3 Fusion	(diagnostic)	Diagnostic	A	Supports Positive	4	accepted	EID8332 This is the first study showing the ETV6-NTRK3 gene fusion in congenital fibrosarcoma (CFS). Using cytogenetic and FISH analyses, a novel t(12;15)(p13;q25) rearrangement was identified in CFS cases (3… (full text at CIViC) PMID 9462753 · Knezevich et al., 1998 · Open in CIViC	civic
ETV6::NTRK3 Fusion	(diagnostic)	Diagnostic	B	Supports Positive	3	accepted	EID11276 In this study, a collection of pediatric spindle cell tumors were screened for the ETV6::NTRK3 fusion by RT-PCR. 10 of 11 (91%) cases diagnosed as congenital fibrosarcoma were found to harbor the ETV… (full text at CIViC) PMID 10895816 · Bourgeois et al., 2000 · Open in CIViC	civic
ETV6::NTRK3 Fusion	(diagnostic)	Diagnostic	B	Supports Positive	3	accepted	EID11277 In this study, the ETV6::NTRK3 fusion was detected in 7 of 10 (70%) of congenital fibrosarcomas by RT-PCR but absent in 38 other control spindle cell tumors, including adult-type fibrosarcomas, leiom… (full text at CIViC) PMID 11242790 · Sheng et al., 2001 · Open in CIViC	civic
ETV6::NTRK3 Fusion	(oncogenic)	Oncogenic	C	Supports Oncogenicity	3	accepted	EID10502 A novel and recurrent t(12;15)(p13;q25) translocation was identified in all three cases of congenital fibrosarcoma (CFS) studied. Molecular cloning of the breakpoints revealed that this translocation … (full text at CIViC) PMID 9462753 · Knezevich et al., 1998 · Open in CIViC	civic
ETV6::NTRK3 Fusion	Entrectinib	Predictive	C	Supports Sensitivity Response	2	submitted	EID11858 In a phase 1/2 trial of entrectinib in pediatric patients, tumors with fusions in NTRK, ROS1, or ALK had an overall response (ORR) of 57.7% (95% CI; 36.9-76.7). This included a patient with infantile… (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC	civic
ETV6::NTRK3 Fusion	Larotrectinib	Predictive	A	Supports Sensitivity Response	4	accepted	EID6099 Four out of six patients with infantile fibrosarcoma and a ETV6-NTRK3 fusion had a partial response, the remaining two had a complete response with larotrectinib. Treatment was done within a multicent… (full text at CIViC) PMID 29606586 · Laetsch et al., 2018 · Open in CIViC	civic
ETV6::NTRK3 Fusion	Larotrectinib	Predictive	C	Supports Sensitivity Response	2	accepted	EID6473 Nagasubramanian et al reports on a case of refractory infantile fibrosarcoma (IFS) with constitutive activation of the tropomyosin‐related kinase (TRK) signaling pathway from an ETS variant gene 6–neu… (full text at CIViC) PMID 27093299 · Nagasubramanian et al., 2016 · Open in CIViC	civic
ETV6::NTRK3 Fusion	Larotrectinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID7418 In a pediatric phase 1 trial (NCT02637687) after initial chemotherapy failure, two ETV6-NTRK3 positive children (2 year old and 5 month old) were treated with Larotrectinib, resulting in reduced tumor… (full text at CIViC) PMID 30204247 · DuBois et al., 2018 · Open in CIViC	civic
ETV6::NTRK3 Fusion	Larotrectinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID10717 This case report describes a male infant with a recurrent (post-resection) infantile fibrosarcoma (IFS) with lymph node involvement and ETV6-NTRK3 fusion. The tumor did not respond to chemotherapy but… (full text at CIViC) PMID 32223937 · Bielack et al., 2019 · Open in CIViC	civic

Infantile Fibrosarcoma9

ETV6::NTRK3 Fusion

(diagnostic)

Diagnostic

Supports Positive

accepted

EID8332

This is the first study showing the ETV6-NTRK3 gene fusion in congenital fibrosarcoma (CFS). Using cytogenetic and FISH analyses, a novel t(12;15)(p13;q25) rearrangement was identified in CFS cases (3… (full text at CIViC)

PMID 9462753 · Knezevich et al., 1998 · Open in CIViC

ETV6::NTRK3 Fusion

(diagnostic)

Diagnostic

Supports Positive

accepted

EID11276

In this study, a collection of pediatric spindle cell tumors were screened for the ETV6::NTRK3 fusion by RT-PCR. 10 of 11 (91%) cases diagnosed as congenital fibrosarcoma were found to harbor the ETV… (full text at CIViC)

PMID 10895816 · Bourgeois et al., 2000 · Open in CIViC

ETV6::NTRK3 Fusion

(diagnostic)

Diagnostic

Supports Positive

accepted

EID11277

In this study, the ETV6::NTRK3 fusion was detected in 7 of 10 (70%) of congenital fibrosarcomas by RT-PCR but absent in 38 other control spindle cell tumors, including adult-type fibrosarcomas, leiom… (full text at CIViC)

PMID 11242790 · Sheng et al., 2001 · Open in CIViC

ETV6::NTRK3 Fusion

(oncogenic)

Oncogenic

Supports Oncogenicity

accepted

EID10502

A novel and recurrent t(12;15)(p13;q25) translocation was identified in all three cases of congenital fibrosarcoma (CFS) studied. Molecular cloning of the breakpoints revealed that this translocation … (full text at CIViC)

PMID 9462753 · Knezevich et al., 1998 · Open in CIViC

ETV6::NTRK3 Fusion

Predictive

Supports Sensitivity Response

submitted

EID11858

In a phase 1/2 trial of entrectinib in pediatric patients, tumors with fusions in NTRK, ROS1, or ALK had an overall response (ORR) of 57.7% (95% CI; 36.9-76.7). This included a patient with infantile… (full text at CIViC)

PMID 35395680 · Desai et al., 2022 · Open in CIViC

ETV6::NTRK3 Fusion

Predictive

Supports Sensitivity Response

accepted

EID6099

Four out of six patients with infantile fibrosarcoma and a ETV6-NTRK3 fusion had a partial response, the remaining two had a complete response with larotrectinib. Treatment was done within a multicent… (full text at CIViC)

PMID 29606586 · Laetsch et al., 2018 · Open in CIViC

ETV6::NTRK3 Fusion

Predictive

Supports Sensitivity Response

accepted

EID6473

Nagasubramanian et al reports on a case of refractory infantile fibrosarcoma (IFS) with constitutive activation of the tropomyosin‐related kinase (TRK) signaling pathway from an ETS variant gene 6–neu… (full text at CIViC)

PMID 27093299 · Nagasubramanian et al., 2016 · Open in CIViC

ETV6::NTRK3 Fusion

Predictive

Supports Sensitivity Response

accepted

EID7418

In a pediatric phase 1 trial (NCT02637687) after initial chemotherapy failure, two ETV6-NTRK3 positive children (2 year old and 5 month old) were treated with Larotrectinib, resulting in reduced tumor… (full text at CIViC)

PMID 30204247 · DuBois et al., 2018 · Open in CIViC

ETV6::NTRK3 Fusion

Predictive

Supports Sensitivity Response

accepted

EID10717

This case report describes a male infant with a recurrent (post-resection) infantile fibrosarcoma (IFS) with lymph node involvement and ETV6-NTRK3 fusion. The tumor did not respond to chemotherapy but… (full text at CIViC)

PMID 32223937 · Bielack et al., 2019 · Open in CIViC

Malignant Neoplasm2
ETV6::NTRK3 Fusion	Entrectinib	Predictive	D	Supports Sensitivity Response	2	submitted	EID11087 BaF3 cells transduced with a number of NTRK fusions demonstrated sensitivity to entrectinib. IC50 values were measured from cell viability assays (Cell Titer Glo) following 72-hour incubation with ent… (full text at CIViC) PMID 26884591 · Drilon et al., 2016 · Open in CIViC	civic
ETV6::NTRK3 Fusion AND NTRK3 G623R	ALK/TRK Inhibitor TSR-011 + Crizotinib + Entrectinib + LarotrectinibSubstitutes	Predictive	D	Supports Resistance	3	accepted	EID10093 BaF3 cells were transduced with an ETV6-NTRK3 fusion construct with or without the additional NTRK3 G623R resistance mutation. These cells were then treated with common Trk inhibitors to measure the r… (full text at CIViC) PMID 26884591 · Drilon et al., 2016 · Open in CIViC	civic

Malignant Neoplasm2

ETV6::NTRK3 Fusion

Predictive

Supports Sensitivity Response

submitted

EID11087

BaF3 cells transduced with a number of NTRK fusions demonstrated sensitivity to entrectinib. IC50 values were measured from cell viability assays (Cell Titer Glo) following 72-hour incubation with ent… (full text at CIViC)

PMID 26884591 · Drilon et al., 2016 · Open in CIViC

ETV6::NTRK3 Fusion AND NTRK3 G623R

ALK/TRK Inhibitor TSR-011 + Crizotinib + Entrectinib + LarotrectinibSubstitutes

Predictive

Supports Resistance

accepted

EID10093

BaF3 cells were transduced with an ETV6-NTRK3 fusion construct with or without the additional NTRK3 G623R resistance mutation. These cells were then treated with common Trk inhibitors to measure the r… (full text at CIViC)

PMID 26884591 · Drilon et al., 2016 · Open in CIViC

Melanoma1
ETV6::NTRK3 Fusion	Entrectinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID11857 In a phase 1/2 trial of entrectinib in pediatric patients, tumors with fusions in NTRK, ROS1, or ALK had an overall response (ORR) of 57.7% (95% CI; 36.9-76.7). This included a patient with melanoma … (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC	civic

Melanoma1

ETV6::NTRK3 Fusion

Predictive

Supports Sensitivity Response

accepted

EID11857

PMID 35395680 · Desai et al., 2022 · Open in CIViC

Solid Neoplasm1
ETV6::NTRK3 Fusion	Larotrectinib	Predictive	A	Supports Sensitivity Response	3	accepted	EID7496 In this phase 1 dose-escalation study seventy patients with metastatic solid tumours were enrolled. Eight patient tumours were found to harbour NTRK gene fusions, six of which were ETV6-NTRK3. Treatme… (full text at CIViC) PMID 30624546 · Hong et al., 2019 · Open in CIViC	civic

Solid Neoplasm1

ETV6::NTRK3 Fusion

Predictive

Supports Sensitivity Response

accepted

EID7496

In this phase 1 dose-escalation study seventy patients with metastatic solid tumours were enrolled. Eight patient tumours were found to harbour NTRK gene fusions, six of which were ETV6-NTRK3. Treatme… (full text at CIViC)

PMID 30624546 · Hong et al., 2019 · Open in CIViC

Thyroid Gland Papillary Carcinoma1

Thyroid Gland Papillary Carcinoma1
ETV6::NTRK3 Fusion	(prognostic)	Prognostic	B	Supports Poor Outcome	3	accepted	EID6474 Prasad et al queried the histopathology of 28 Papillary Thyroid Carcinomas (PTCs) from patients ages 6-18 years (20 females, 8 males). None had significant exposure to radiation. 5 / 27 PTCs (18.5%) h… (full text at CIViC) PMID 26784937 · Prasad et al., 2016 · Open in CIViC	civic

ETV6::NTRK3 Fusion

(prognostic)

Prognostic

Supports Poor Outcome

accepted

EID6474

Prasad et al queried the histopathology of 28 Papillary Thyroid Carcinomas (PTCs) from patients ages 6-18 years (20 females, 8 males). None had significant exposure to radiation. 5 / 27 PTCs (18.5%) h… (full text at CIViC)

PMID 26784937 · Prasad et al., 2016 · Open in CIViC

Childhood B-cell Acute Lymphoblastic Leukemia1unmapped disease
ETV6::NTRK3 Fusion	(diagnostic)	Diagnostic	C	Supports Positive	3	submitted	EID7060 In this study, 264 of 1725 precursor B-ALL cases were identified as being BCR-ABL1 like (Ph-like) based on their expression signature (which was is similar to BCR-ABL1 positive cases); of those, one c… (full text at CIViC) PMID 25207766 · Roberts et al., 2014 · Open in CIViC	civic

Childhood B-cell Acute Lymphoblastic Leukemia1unmapped disease

ETV6::NTRK3 Fusion

(diagnostic)

Diagnostic

Supports Positive

submitted

EID7060

In this study, 264 of 1725 precursor B-ALL cases were identified as being BCR-ABL1 like (Ph-like) based on their expression signature (which was is similar to BCR-ABL1 positive cases); of those, one c… (full text at CIViC)

PMID 25207766 · Roberts et al., 2014 · Open in CIViC

Low-grade Mucinous Bronchial Adenocarcinoma1unmapped disease
ETV6::NTRK3 Fusion	(oncogenic)	Oncogenic	C	Supports Oncogenicity	1	submitted	EID10422 ETV6-NTRK3 translocation has shown to be associated with low-grade mucinous bronchial adenocarcinoma case PMID 33895680 · von der Thüsen et al., 2021 · Open in CIViC	civic

Low-grade Mucinous Bronchial Adenocarcinoma1unmapped disease

ETV6::NTRK3 Fusion

(oncogenic)

Oncogenic

Supports Oncogenicity

submitted

EID10422

ETV6-NTRK3 translocation has shown to be associated with low-grade mucinous bronchial adenocarcinoma case

PMID 33895680 · von der Thüsen et al., 2021 · Open in CIViC

Mammary Analogue Secretory Carcinoma4unmapped disease
ETV6::NTRK3 Fusion	Crizotinib	Predictive	C	Does Not Support Sensitivity Response	2	accepted	EID1870 Case report of a patient with mammary analogue secretory carcinoma (MASC) harboring an ETV6-NTRK3 fusion. The patient was treated with crizotinib and had stable disease but disease progression after 1… (full text at CIViC) PMID 26884591 · Drilon et al., 2016 · Open in CIViC	civic
ETV6::NTRK3 Fusion	Entrectinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID1869 Case report of a patient with mammary analogue secretory carcinoma (MASC) harboring an ETV6-NTRK3 fusion. The patient was treated with entrectinib and exhibited a partial response for 7 months followe… (full text at CIViC) PMID 26884591 · Drilon et al., 2016 · Open in CIViC	civic
ETV6::NTRK3 Fusion	Entrectinib	Predictive	C	Supports Sensitivity Response	3	submitted	EID10692 A patient with recurrent metastatic salivary secretory carcinoma and ETV6-NTRK3 fusion was treated with entrectinib and achieved durable ongoing response. The patient had partial response after 4 week… (full text at CIViC) PMID 35735423 · Ernst et al., 2022 · Open in CIViC	civic
ETV6::NTRK3 Fusion AND NTRK3 G623R	Entrectinib	Predictive	C	Supports Resistance	4	accepted	EID1874 Case report of a patient with mammary analogue secretory carcinoma (MASC) harboring an etv6-ntrk3 fusion. The patient was treated with entrectinib and exhibited a partial response for 7 months followe… (full text at CIViC) PMID 26884591 · Drilon et al., 2016 · Open in CIViC	civic

Mammary Analogue Secretory Carcinoma4unmapped disease

ETV6::NTRK3 Fusion

Crizotinib

Predictive

Does Not Support Sensitivity Response

accepted

EID1870

Case report of a patient with mammary analogue secretory carcinoma (MASC) harboring an ETV6-NTRK3 fusion. The patient was treated with crizotinib and had stable disease but disease progression after 1… (full text at CIViC)

PMID 26884591 · Drilon et al., 2016 · Open in CIViC

ETV6::NTRK3 Fusion

Predictive

Supports Sensitivity Response

accepted

EID1869

Case report of a patient with mammary analogue secretory carcinoma (MASC) harboring an ETV6-NTRK3 fusion. The patient was treated with entrectinib and exhibited a partial response for 7 months followe… (full text at CIViC)

PMID 26884591 · Drilon et al., 2016 · Open in CIViC

ETV6::NTRK3 Fusion

Predictive

Supports Sensitivity Response

submitted

EID10692

A patient with recurrent metastatic salivary secretory carcinoma and ETV6-NTRK3 fusion was treated with entrectinib and achieved durable ongoing response. The patient had partial response after 4 week… (full text at CIViC)

PMID 35735423 · Ernst et al., 2022 · Open in CIViC

ETV6::NTRK3 Fusion AND NTRK3 G623R

Predictive

Supports Resistance

accepted

EID1874

Case report of a patient with mammary analogue secretory carcinoma (MASC) harboring an etv6-ntrk3 fusion. The patient was treated with entrectinib and exhibited a partial response for 7 months followe… (full text at CIViC)

PMID 26884591 · Drilon et al., 2016 · Open in CIViC